HEOR Structure & Interactions

For internal use only

Cross-Functional Engagement Map

HEOR Internal Partnerships

Click any team to explore how HEOR collaborates across the organization. Color reflects interaction intensity.

HEOR VALUE EVIDENCE
↖
Select any team from the diagram to view HEOR's collaboration touchpoints.
Global Biopharma · HEOR Reporting into Medical Affairs

HEOR Organizational Structure

Click any node to expand or collapse. HEOR sits within Global Medical Affairs, enabling deep integration with evidence generation, publications, and MSL field teams.

Health Economics
Cost-effectiveness, CEA, and budget impact models powering HTA submissions to NICE, ICER, G-BA, CADTH, and payer formulary committees.
Real-World Evidence
Observational studies using claims, EHR, and patient registries to validate trial outcomes in routine clinical practice and support label expansions.
Patient-Reported Outcomes
Validation of PRO instruments; QoL and burden-of-illness research anchoring the humanistic value narrative for payers and guideline bodies.
Global Value & Evidence
HTA strategy, global value dossiers (GVDs), and evidence synthesis translating clinical data into reimbursement-ready value stories across geographies.
Why HEOR Sits in Medical Affairs
Scientific Credibility
Positions HEOR outputs as independent, evidence-based — critical for HTA and payer trust.
MSL Alignment
HEOR data directly equips Medical Science Liaisons for payer and KOL engagement.
Publication Integration
Seamless coordination with Global Publications for RWE and outcomes research dissemination.
Trial Endpoint Design
Close partnership with R&D to embed PROs and HEOR endpoints from Phase II onward.
Global HTA Coordination
Medical Affairs infrastructure supports local adaptation of value dossiers across markets.
Supplier Ecosystem & Sourcing Workflow

External Interactions

How HEOR teams engage external partners — from vendor selection through payment — and the procurement challenges that shape this process.

🏢
HEOR Consultancies
Specialize in model development, PRO validation, literature reviews, and payer value communications.
e.g., ICON, RTI Health Solutions, Pharmerit
📊
RWE Data Providers & Analytics Firms
Provide data access, statistical analyses, and study execution capabilities.
e.g., IQVIA, Flatiron, TriNetX, OM1
🎓
Academic Collaborators
Partner for scientific credibility, peer-reviewed publications, and methodological rigor.
Leading academic medical centers & research institutes
🔬
CROs / Hybrid Providers
Manage study logistics, database build, site engagement, and regulatory documentation.
Full-service and specialty CROs
💻
Technology & HEOR Platform Providers
Provide tools that enable internal HEOR scale and analytical efficiency.
e.g., Aetion, TreeAge
🧩
Fragmented & Highly Specialized Supplier Landscape
  • HEOR services rely on a diverse ecosystem of consultancies, analytics firms, academic groups, and real-world data providers.
  • Many studies require niche expertise tied to specific therapeutic areas, geographies, datasets, or methodologies.
  • Procurement teams frequently need to identify and onboard new suppliers to meet evolving evidence-generation needs.
  • Establishing new vendor relationships can take months due to due diligence, risk review, and contracting processes.
🔍
Limited Visibility Into HEOR Spend & Supplier Performance
  • HEOR budgets may be centrally allocated, but sourcing activity, quotes, and supplier engagement are often tracked across multiple systems or spreadsheets.
  • Procurement teams often lack line-level data on study budgets, supplier rates, and vendor performance.
  • Without structured data, it is difficult to benchmark pricing, identify consolidation opportunities, monitor preferred supplier usage, or develop informed category strategies.
⚖️
High Administrative Burden Relative to Category Size
  • HEOR typically represents a relatively small portion of total R&D or commercial spend, leading to limited dedicated procurement resources.
  • Despite the smaller budget footprint, teams must still manage proposal comparisons, supplier onboarding, contracting and SOW execution, and invoice coordination.
  • This creates a disproportionate administrative burden on procurement teams already managing multiple categories.
📈
Difficulty Scaling Evidence Generation Efficiently
  • Demand for HEOR and RWE studies continues to grow as biopharma companies rely more heavily on evidence to support pricing, reimbursement, and market access decisions.
  • Supporting this demand requires coordinating multiple studies across therapeutic areas and suppliers simultaneously.
  • Without standardized sourcing workflows and centralized supplier access, scaling HEOR programs can become slow and operationally inefficient.